XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Total Stockholders’ Equity attributable to Privia Health Group, Inc.
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Non-controlling Interest
Beginning Balance (in shares) at Dec. 31, 2020     95,985,817      
Beginning Balance at Dec. 31, 2020 $ 143,652 $ 146,748 $ 960 $ 165,666 $ (19,878) $ (3,096)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon closing of initial public offering (in shares)     9,725,000      
Issuance of common stock upon closing of initial public offering 210,994 210,994 $ 97 210,897    
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     2,126,924      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 3,829 3,829 $ 21 3,808    
Stock-based compensation expense 253,531 253,531   253,531    
Contributed non-controlling interest 28,824         28,824
Net income (loss) (190,649) (188,230)     (188,230) (2,419)
Ending Balance (in shares) at Dec. 31, 2021     107,837,741      
Ending Balance at Dec. 31, 2021 450,181 426,872 $ 1,078 633,902 (208,108) 23,309
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     6,853,067      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 13,448 13,448 $ 70 13,378    
Stock-based compensation expense 67,359 67,359   67,359    
Contributed non-controlling interest 125         125
Net income (loss) $ (12,064) (8,585)     (8,585) (3,479)
Ending Balance (in shares) at Dec. 31, 2022 114,690,808   114,690,808      
Ending Balance at Dec. 31, 2022 $ 519,049 499,094 $ 1,148 714,639 (216,693) 19,955
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)     3,526,171      
Issuance of common stock upon exercise of stock options and vesting of restricted stock units 8,740 8,740 $ 34 8,706    
Stock-based compensation expense 37,098 37,098   37,098    
Repurchase of non-controlling interest (5,694) (8,871)   (8,871)   3,177
Contributed non-controlling interest 24,871         24,871
Tax effect related to purchase of non-controlling interest 2,297 2,297   2,297    
Net income (loss) $ 21,028 23,079     23,079 (2,051)
Ending Balance (in shares) at Dec. 31, 2023 118,216,979   118,216,979      
Ending Balance at Dec. 31, 2023 $ 607,389 $ 561,437 $ 1,182 $ 753,869 $ (193,614) $ 45,952